Brief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
22/10/2024 06:31
Oct 22 (Reuters) - Crossject SA 74C.F :
* CROSSJECT REPORTS STRONG MANUFACTURING PROGRESS WITH ITS
EPILEPSY RESCUE THERAPY ZEPIZURE® AHEAD OF FILING U.S. EMERGENCY
USE AUTHORIZATION
* CROSSJECT SA - EXPECTS TO FILE FOR EUA EARLY NEXT YEAR
* CROSSJECT SA - TO MANUFACTURE FIRST COMMERCIAL BATCHES IN
EARLY
2025
Source text for Eikon: ID:nGNX11g6x1
Further company coverage: 74C.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure